甘利欣联合复方丹参抗肝纤维化的疗效研究

Observation on therapeutic effect of diammonium glycyrrihizinate combined with salv against liver fibrosis

目的:探讨甘利欣联合丹参对慢性肝炎肝纤维化的治疗作用。方法:将90例慢性乙型肝炎患者分为治疗组(予甘利欣150mg加丹参20m l治疗)、甘利欣组(予甘利欣150mg治疗)和丹参组(予丹参20m l治疗),分别加入5%葡萄糖注射液250m l静脉滴注,1次/d,2个月为1个疗程,治疗1个疗程。比较治疗前后检测各组肝功能及肝纤维化血清学指标。结果:治疗组治疗后肝功能及肝纤维化指标明显好转,与治疗前及甘利欣组、丹参组比较,差异有统计学意义(P<0.05)。结论:甘利欣联合丹参对慢性肝炎有明显的抗纤维化作用,比单用效果要好。

Objective To study the treatment effect of diammonium glycyrrihizinate combined with san against liver fibrosis in chronie hepatitis. Method Total 90 patients with chronic hepatitis were divided into the treatment group（ diammonium glycyrrihizinate 150 mg combined with salv 20 ml） ,the diammonium glycyrrhizinate group（ diammonium glycyrrhizinate 150mg） and the salv group （ salv 20 ml）. The above drugs were fixed with 5% glucose solution 250 ml by intravenous injection （qd,2 months as a course） and the patients were treated for 1 course. Liver function and serum hepatic fibrosis markers between the 3 groups before and after treatment were compared. Results The liver function and serum hepatic fibrosis markers in the treatment group were better than that of before treatment ,and had significant differences compared with before treatment, the diammonium glycyrrhizinate group and salv group （ P 〈 0. 05 ）. Conclusion There is obvious effect of diammonium glycyn＇ihizinate combined with salv against liver fibrosis, and it is much better than each single used.